{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-117256","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.905724+00:00","generated_at":"2026-06-22T00:27:42.932855+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Theriva Biologics Q3 2022 cash $50.5M; FDA clears Phase 2 trial for VCN-01 in PDAC","bullets":["Cash and cash equivalents $50.5M as of Sep 30, 2022; expected runway into Q1 2024.","FDA and AEMPS cleared the planned Phase 2 trial of VCN-01 in pancreatic ductal adenocarcinoma patients.","SYN-004 Phase 1b/2a in allo-HCT: positive DSMC review for Cohort 1; first patient dosed in Cohort 2 (Oct 2022).","Company rebranded as Theriva Biologics and began trading under ticker TOVX on NYSE American in October 2022.","Anticipated near-term milestones: initiate VIRAGE Phase 2 for VCN-01 in PDAC Q4 2022; pre-IND meeting for retinoblastoma early 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-117256","json":"https://secwatch.observer/filing/0001104659-22-117256.json","markdown":"https://secwatch.observer/filing/0001104659-22-117256.md","text":"https://secwatch.observer/filing/0001104659-22-117256.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465922117256/0001104659-22-117256-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465922117256/tm2230285d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T00:27:42.932855+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d369e65b46b62f13bc4141e8a532f68ef19d7542","claim":"Theriva Biologics, Inc. reported financial results for for the quarter ended September 30, 2022.","evidence_excerpt":"On November 10, 2022, Theriva Biologics, Inc., a Nevada corporation (the “Registrant”) issued a press release that included financial information for its quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/894158/000110465922117256/0001104659-22-117256-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}